Biocon’s U.S. Denosumab Biosimilars Launch: A Strategic Inflection Point for the Bone Health Market
On April 7, 2026, Biocon marked a significant milestone with the U.S. commercial launch of Bosaya™ and Aukelso™, its interchangeable denosumab biosimilars referencing blockbuster biologics…
